Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)

Completed · Phase 2

Conditions studied: Colorectal Neoplasms

In brief

This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).

Key facts

Study ID: NCT03631407
Run by: Merck Sharp & Dohme LLC
People needed: 41
Starts: 2018-09-24
Expected to finish: 2021-06-08
Last updated by the study team: 2024-11-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Have a histologically proven locally advanced unresectable or metastatic CRC.
Have locally confirmed MSS CRC.
Have been previously treated with standard therapies, which must include fluoropyrimidine, oxaliplatin, and irinotecan, and have received, been intolerant to, or been ineligible for all treatment known to confer clinical benefit.
Have measurable disease per RECIST 1.1 as assessed by the local site investigator/radiology.
Have provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days of starting study intervention.
Male participants must agree to use contraception and refrain from donating sperm for at least 120 days after the last dose of study intervention.
Female participants must be not pregnant and not breastfeeding. Further, a female participant must either not be a woman of childbearing potential (WOCBP) or, if a WOCBP, agree to use contraception during the treatment period and for at least 120 days after the last dose of study intervention.
Have adequate organ function.

You may not qualify if…

Have a known additional malignancy that is progressing or has required active treatment within the past 2 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
Have known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
Have severe hypersensitivity reaction to treatment with any monoclonal antibody or components of the study interventions.
Have an active autoimmune disease requiring systemic treatment in the past 2 years, except vitiligo or resolved childhood asthma/atopy.
Have a history of vasculitis.
Have an active infection requiring systemic therapy.
Have symptomatic ascites or pleural effusion.
Have interstitial lung disease requiring oral or IV glucocorticoids.
Have a history of pneumonitis (noninfectious) that required steroids, or has current pneumonitis.
Have a known history of human immunodeficiency virus (HIV) infection.
Have a known history of hepatitis B or known active hepatitis C virus infection.
Have a known history of active tuberculosis (TB; Bacillus tuberculosis).
Have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, make administration of the study interventions hazardous, or make it difficult to monitor adverse events.
Have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with study requirements.
Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the Screening Visit through 120 days after the last dose of study intervention.
Are a WOCBP who has a positive urine pregnancy test within 72 hours before randomization or treatment allocation.
Have undergone major surgery and have not recovered adequately from any toxicity and/or complications from the intervention before starting study intervention.
Have a seizure disorder requiring ongoing antiseizure therapy or with any condition that, in the judgment of the investigator, is likely to increase the risk of seizure (e.g., CNS malignancy or toxoplasmosis).
Have known gastrointestinal (GI) disease such as esophageal, gastric, or duodenal ulceration or inflammatory bowel disease, or history of GI surgery.
Are using any drug (therapeutic or recreational), or withdrawal thereof, that poses an increased risk of convulsions.
Have had an allogeneic tissue/solid organ transplant.
Have received prior therapy with vicriviroc or other CCR5 antagonist (e.g., maraviroc) or have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent.
Have been treated with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX 40, CD137).
Have received prior systemic anticancer therapy, including investigational agents, or has used an investigational device within 28 days before the first dose of study intervention.
Have received prior radiotherapy (not to target lesions) within 2 weeks of start of study intervention.

Where it is running

Honor Health ( Site 0103) — Scottsdale, Arizona, United States
California Cancer Associates for Research & Excellence ( Site 0100) — Encinitas, California, United States
California Cancer Associates for Research & Excellence ( Site 0102) — Fresno, California, United States
Florida Cancer Specialists (South Region) - Research Office ( Site 7001) — Fort Myers, Florida, United States
Tennessee Oncology, PLLC/The Sarah Cannon Research Institute ( Site 7000) — Nashville, Tennessee, United States
Baylor Scott & White Medical Center - Temple ( Site 0104) — Temple, Texas, United States
Cross Cancer Institute ( Site 0201) — Edmonton, Alberta, Canada
CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 0204) — Montreal, Quebec, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.